Skip to main content

TFF Pharmaceuticals, Inc. (TFFP)

NASDAQ: TFFP · Delayed Price · USD
8.11 0.02 (0.25%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap205.77M
Revenue (ttm)26,165
Net Income (ttm)-23.26M
Shares Out25.37M
EPS (ttm)-1.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume287,278
Open8.10
Previous Close8.09
Day's Range7.84 - 8.33
52-Week Range6.87 - 21.14
Betan/a
AnalystsBuy
Price Target25.00 (+208.3%)
Est. Earnings DateNov 4, 2021

About TFFP

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacr...

IndustryPharmaceuticals
IPO DateOct 25, 2019
Employees4
Stock ExchangeNASDAQ
Ticker SymbolTFFP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is 25.00, which is an increase of 208.26% from the latest price.

Price Target
$25.00
(208.26% upside)
Analyst Consensus: Buy

News

TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products ...

2 weeks ago - GlobeNewsWire

TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021

1 month ago - GlobeNewsWire

Augmenta - TFF Pharma's COVID-19 Antibody Shows Preclinical Activity Against Delta Variant

Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ: TFFP) have announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody, AUG-3387, binds to and neutralizes the SA...

1 month ago - Benzinga

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of...

Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays

1 month ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference

AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products b...

1 month ago - GlobeNewsWire

TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study

TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.

2 months ago - Zacks Investment Research

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrol...

Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels  Anticipate Additional Safety Data in 3Q 2021  Initiation of Lung Transplant Study Expected in 2H 2021

2 months ago - GlobeNewsWire

New Strong Sell Stocks for July 8th

CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021

Other symbols:CLPRIONSRADVNCE
2 months ago - Zacks Investment Research

New Strong Sell Stocks for June 28th

BNL, CANG, TFFP, AJRD and SJW have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2021.

Other symbols:AJRDBNLCANGSJW
2 months ago - Zacks Investment Research

TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19

Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ: TFFP) have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their joint development Collabor...

3 months ago - Benzinga

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clini...

AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants AUG-3387 Active Against All Variants Tested Including the U...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

AUSTIN, Texas, May 25, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products ba...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals reports first quarter 2021 financial results and provides business update. Conference call today at 4:30pm EDT.

4 months ago - Business Wire

TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold first quarter 2021 financial and business results conference call on May 13, 2021 at 4:30 PM EDT

4 months ago - Business Wire

TFF Pharmaceuticals Awarded Contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S...

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #DARPA--TFF Pharmaceuticals awarded contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S. warfighters.

5 months ago - Business Wire

TFF Pharmaceuticals Prices Offering of Common Stock

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals prices offering of common stock

5 months ago - Business Wire

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals (NASDAQ: TFFP), reports Fourth Quarter and Full Year 2020 financial and business results. Conference call today at 4:30pm EST.

6 months ago - Business Wire

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

RADNOR, Pa. and AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material tra...

6 months ago - PRNewsWire

Feasibility Arrangement for Shelf-stable Powder Form of Messenger RNA COVID-19 Vaccine Candidate Announced by GreenLi...

MEDFORD, Mass. & AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #COVID--GreenLight Biosciences and TFF Pharmaceuticals enter into feasibility arrangement for shelf-stable powder form of messenger RNA COVID-19...

6 months ago - Business Wire

Why Earnings Season Could Be Great for TFF Pharmaceuticals (TFFP)

TFF Pharmaceuticals (TFFP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals to Present at the upcoming H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference in March.

6 months ago - Business Wire

TFF Pharmaceuticals Provides Update on Clinical Development Programs

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #tacrolimus--TFF Pharmaceuticals provides update on its clinical development programs for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

6 months ago - Business Wire

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call ...

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold its fourth quarter and full-year 2020 financial results and business results conference call on March 10, 2021.

6 months ago - Business Wire

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States ...

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #Ebola--TFF Pharmaceuticals reports positive preclinical results with two biodefense countermeasures for the Army's USAMRIID laboratories.

7 months ago - Business Wire

TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its paten...

7 months ago - Business Wire